Biocon Q2 Profit Drops 52%, Company Says Q2 Softness Temporary, Expects Stronger H2FY27
Business Today · 05 Nov 2026 · 19 min
Management interview of Biocon Ltd (BIOCON), with 8 key numbers discussed.
- Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited
Biocon reported that Q2 profitability was impacted by logistics-related sales deferrals of approximately USD 20mn, which affected EBITDA and profit margins. Management expects a strong rebound in H2FY27 led by biosimilars growth, rising US insulin demand, and the newly operationalized second fill-finish line in Malaysia. The company secured a 10-year, USD 400mn fixed-price contract for pertuzumab in Brazil and plans a European launch in Q4 FY27, followed by a US entry in 2028. Management also highlighted differentiation in the GLP-1 peptide space through dedicated device platforms and international partnerships.